SEC Form 5 · accession 0000899243-19-003695

Eidos Therapeutics, Inc. · EIDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Neil Kumar

Officer — Chief Executive Officer · Director · 10% Owner

Period of report

Dec 31, 2018

Accepted (ET)

Feb 14, 2019 · 6:19 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001731831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 3, 2018	P	1,750,000	$15.50	A	21,364,655	I	See Footnote
Common Stock^F1	Dec 5, 2018	P	1,103,848	$14.01	A	22,468,503	I	See Footnote
Common Stock^F2,F1	Dec 6, 2018	P	38,970	$13.34	A	22,507,473	I	See Footnote
Common Stock^F3,F1	Dec 7, 2018	P	36,314	$13.94	A	22,543,787	I	See Footnote
Common Stock^F4,F1	Dec 7, 2018	P	4,860	$14.36	A	22,548,647	I	See Footnote
Common Stock^F5,F1	Dec 10, 2018	P	37,989	$13.29	A	22,586,636	I	See Footnote
Common Stock^F6,F1	Dec 10, 2018	P	2,664	$13.96	A	22,589,300	I	See Footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
F2Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F3Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F4Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F5Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F6Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.